These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17717337)

  • 1. NICE's cost effectiveness threshold.
    Appleby J; Devlin N; Parkin D
    BMJ; 2007 Aug; 335(7616):358-9. PubMed ID: 17717337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NICE's cost-effectiveness range: should it be lowered?
    Raftery JP
    Pharmacoeconomics; 2014 Jul; 32(7):613-5. PubMed ID: 24811892
    [No Abstract]   [Full Text] [Related]  

  • 3. Experts disagree over NICE's approach for assessing drugs.
    Hoey R
    Lancet; 2007 Aug; 370(9588):643-4. PubMed ID: 17726791
    [No Abstract]   [Full Text] [Related]  

  • 4. Some inconsistencies in NICE's consideration of social values.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?
    Getsios D; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2007; 25(12):997-1006. PubMed ID: 18047386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Bosanquet N; Yeates A
    Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908
    [No Abstract]   [Full Text] [Related]  

  • 7. Should NICE's threshold range for cost per QALY be raised? No.
    Raftery J
    BMJ; 2009 Jan; 338():b185. PubMed ID: 19171562
    [No Abstract]   [Full Text] [Related]  

  • 8. Should NICE's threshold range for cost per QALY be raised? Yes.
    Towse A
    BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561
    [No Abstract]   [Full Text] [Related]  

  • 9. Crossing the line: NICE's value for money threshold.
    Appleby J
    BMJ; 2016 Mar; 352():i1336. PubMed ID: 26960807
    [No Abstract]   [Full Text] [Related]  

  • 10. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease.
    Iliffe S
    CNS Drugs; 2007; 21(3):177-84. PubMed ID: 17338591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
    Paulden M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
    [No Abstract]   [Full Text] [Related]  

  • 12. Review of NICE's recommendations, 1999-2005.
    Raftery J
    BMJ; 2006 May; 332(7552):1266-8. PubMed ID: 16735341
    [No Abstract]   [Full Text] [Related]  

  • 13. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
    O'Mahony JF; Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valued lives: Britain stirs outcry by weighing benefits of drugs versus price; government arm finds pills for Alzheimer's too costly, angering patients, Pfizer.
    Whalen J
    Wall St J (East Ed); 2005 Nov; ():A1, A11. PubMed ID: 16502534
    [No Abstract]   [Full Text] [Related]  

  • 15. Health economics: basic principles and application in mental health.
    Suh GH
    Int Psychogeriatr; 2007 Dec; 19(6):993-1002. PubMed ID: 18161066
    [No Abstract]   [Full Text] [Related]  

  • 16. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NICE cost-effectiveness threshold: what it is and what that means.
    McCabe C; Claxton K; Culyer AJ
    Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Court upholds NICE decision to limit treatments for Alzheimer's disease.
    Dyer O
    BMJ; 2007 Aug; 335(7615):319. PubMed ID: 17703017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.